Genetic changes with prognostic value in histologically benign meningiomas

被引:22
作者
Barbera, Sandra [1 ]
Migue, Teresa San [1 ]
Gil-Benso, Rosario [1 ]
Munoz-Hidalgo, Lisandra [1 ]
Roldan, Pedro [2 ]
Gonzalez-Darder, Jose [2 ]
Cerda-Nicolas, Miguel [1 ]
Lopez-Gines, Concha [1 ]
机构
[1] Univ Valencia, Dept Pathol, Valencia, Spain
[2] Hosp Clin Univ, Dept Neurosurg, Valencia, Spain
关键词
meningioma; recurrence; cytogenetics; chromosome; 1p; 14; MALIGNANT MENINGIOMAS; TUMOR; CHROMOSOME-14; ABNORMALITIES; EPIDEMIOLOGY; PROGRESSION; PATTERNS; MODEL; 1P;
D O I
10.5414/NP300580
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Meningiomas add up to 25% of intracranial tumors. Although the majority is considered histologically benign, the prediction of their potential aggressiveness is still unclear. We studied the histopathology and aberrations of chromosomes 1p, 14, and 22 by FISH (fluorescence in situ hybridization) in histologically benign meningiomas of 70 patients for the purpose of defining the prognostic value of these alterations in tumoral progression and the risk of recurrence. According to the WHO histopathological criteria, the study set comprised 53 benign, 11 atypical, and 6 anaplastic meningiomas. In benign meningiomas, 25% of the cases displayed a normal karyotype, isolated monosomy 22 (36%), monosomy 22 + 1p deletion (14%), 1p deletion (10%), monosomy 22 + 14q deletion (5%), monosomy 22 + 1p deletion + 14q deletion (5%), or other alterations (5%). Grade II meningiomas presented losses in chromosome 14 in most of the cases (67%), and Grade III meningiomas showed alterations in chromosome 14 in all patients. We observed an overall relapse rate of 31%: recurrence was observed in 19% of Grade 1 meningiomas, 64% of Grade II, and 83% of Grade III. 9 out of 10 recurrent cases revealed abnormalities in chromosomes 1 and 14, which was a notably higher incidence compared to the series of tumors without relapse. Thus, benign meningiomas with cytogenetic alterations in chromosomes 1p and 14 may be more closely related to atypical meningiomas than benign meningiomas without these alterations, especially in terms of recurrence risk.
引用
收藏
页码:311 / 317
页数:7
相关论文
共 22 条
[1]   Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines [J].
Ambros, PF ;
Ambros, IM .
MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 37 (06) :492-504
[2]   Epidemiology and etiology of intracranial meningiomas: A review [J].
Bondy, M ;
Ligon, BL .
JOURNAL OF NEURO-ONCOLOGY, 1996, 29 (03) :197-205
[3]  
Cerdá-Nicolás M, 2000, CLIN NEUROPATHOL, V19, P259
[4]  
Enam SA, 1996, ACTA NEUROCHIR, V138, P1172
[5]   Molecular alterations in the neurofibromatosis Type 2 gene and its protein rarely occurring in meningothelial meningiomas [J].
Evans, JJ ;
Jeun, SS ;
Lee, JH ;
Harwalkar, JA ;
Shoshan, Y ;
Cowell, JK ;
Golubic, M .
JOURNAL OF NEUROSURGERY, 2001, 94 (01) :111-117
[6]  
Ishino S, 1998, CANCER, V83, P360, DOI 10.1002/(SICI)1097-0142(19980715)83:2<360::AID-CNCR21>3.0.CO
[7]  
2-Q
[8]  
JAN M, 1986, NEUROCHIRURGIE, V32, P129
[9]   NF2 status of meningiomas is associated with tumour localization and histology [J].
Kros, J ;
de Greve, K ;
van Tilborg, A ;
Hop, W ;
Pieterman, H ;
Avezaat, C ;
Deprez, RLD ;
Zwarthoff, E .
JOURNAL OF PATHOLOGY, 2001, 194 (03) :367-372
[10]  
LONGSTRETH WT, 1993, CANCER, V72, P639, DOI 10.1002/1097-0142(19930801)72:3<639::AID-CNCR2820720304>3.0.CO